On March 8, 2024 Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, reported its participation to the World ADC 2024 summit that will be held in London, UK (World ADC Europe) from March 12th to March 15th, 2024, with a poster presentation entitled (Press release, Nerviano Medical Sciences, MAR 8, 2024, View Source [SID1234640967]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"A payload-linker generating machine to quickly move from small molecules to characterized tool ADCs and PDCs"

NMS, leveraging on its proprietary chemical collection and applying a rigorous screening funnel, generated a portfolio of characterized payload linkers with diversified MoAs to target different tumor types.

Pillars of available technology are: 1) NMS-P945, a ‘plug-and-play’ thienoduocarmycin, active in chemoresistant cells, showing bystander effect and immunogenic cell death properties, highly efficacious in vivo in preclinical models and greater nonclinical safety profile, 2) next generation anthracycline payload linkers with improved stability and safety profile, both DNA damaging agents, 3) novel payloads.

NMS seek for collaborations with partners having an established expertise in biologics to launch new innovative projects.